SANOVO Tests Early EGFR and MET Dual Blockade
New Phase III data presented on 26 October show a large progression-free survival benefit from savolitinib plus osimertinib over osimertinib alone in untreated EGFR-mutant, MET-overexpressing advanced NSCLC in China. Overall-survival findings are promising but…
